4.6 Review

Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review

Journal

SUPPORTIVE CARE IN CANCER
Volume 28, Issue 3, Pages 1369-1383

Publisher

SPRINGER
DOI: 10.1007/s00520-019-04961-4

Keywords

Oncology; Fever; Neutropenia; Time to antibiotics; Cancer; Chemotherapy; Systematic review

Funding

  1. Medical Research Council [G0800472] Funding Source: Medline
  2. Krebsliga Schweiz [KFS-3645-02-2015] Funding Source: Medline
  3. Department of Health [PDF-2014-07-072] Funding Source: Medline
  4. MRC [G0800472] Funding Source: UKRI

Ask authors/readers for more resources

Purpose Prompt antibiotic therapy is standard of care for patients with fever and neutropenia (FN) during chemotherapy for cancer. We systematically reviewed the association between time to antibiotics (TTA) and clinical outcomes. Methods The search covered seven databases; confounding biases and study quality were assessed with the ROBINS-I tool. Safety (death, intensive care unit (ICU) admission, sepsis) and treatment adequacy (relapse of infection, persistence or recurrence of fever) were assessed as primary outcomes. Results Of 6296 articles identified, 13 observational studies were included. Findings regarding safety were inconsistent. Three studies controlling for triage bias showed a possible association between longer TTA and impaired safety. Meta-analysis for TTA <= 60 min versus > 60 min was feasible on four studies, with three studies each reporting on death (OR 0.78, 95%CI 0.16-3.69) and on ICU admission (OR 1.43, 95%CI 0.57-3.60). No study reported data on treatment adequacy. Triage bias, i.e. faster treatment of patients with worse clinical condition, was identified as a relevant confounding factor. Conclusion There seems to be an association between longer TTA and impaired safety. More knowledge about TTA effects on safety are important to optimise treatment guidelines for FN. Controlling for triage and other biases is necessary to gain further evidence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pediatrics

COVID-19 in children with haematological malignancies

Gerard Cathal Millen, Roland Arnold, Jean-Baptiste Cazier, Helen Curley, Richard Feltbower, Ashley Gamble, Adam Glaser, Richard G. Grundy, Laura Kirton, Lennard Y. W. Lee, Martin G. McCabe, Claire Palles, Bob Phillips, Charles A. Stiller, Csilla Varnai, Pamela Kearns

Summary: Children with haematological malignancies are at no greater risk of severe SARS-CoV-2 infection than those with non-haematological malignancies.

ARCHIVES OF DISEASE IN CHILDHOOD (2022)

Article Pediatrics

Mucositis reduction with probiotics in children with cancer: a randomised-controlled feasibility study

Hadeel Hassan, Sally Kinsey, Bob Phillips

Summary: This study aimed to evaluate the feasibility of using probiotics to reduce or prevent mucositis and infection in children with cancer, and found that recruitment needs to be improved before undertaking a sufficiently powered RCT.

ARCHIVES OF DISEASE IN CHILDHOOD (2022)

Article Pediatrics

Low-level laser therapy for oral mucositis in children with cancer

Melody Grace Redman, Katherine Harris, Bob S. Phillips

Summary: The study reviewed the safety and efficacy of low-level laser therapy for oral mucositis in pediatric cancer patients. The results suggest that LLLT may help reduce the severity of oral mucositis and oral pain, but further randomized controlled trials are needed to confirm these findings. The lack of blinding in some studies introduced a risk of bias, indicating a need for more robust research to determine the true effectiveness of LLLT for treating oral mucositis in children with cancer.

ARCHIVES OF DISEASE IN CHILDHOOD (2022)

Letter Pediatrics

Towards evidence-based medicine for paediatricians

Bob Phillips

ARCHIVES OF DISEASE IN CHILDHOOD (2022)

Editorial Material Pediatrics

Towards evidence-based medicine for paediatricians

Bob Phillips

ARCHIVES OF DISEASE IN CHILDHOOD (2022)

Article Multidisciplinary Sciences

Time to antibiotics is unrelated to outcome in pediatric patients with fever in neutropenia presenting without severe disease during chemotherapy for cancer

Christa Koenig, Claudia E. Kuehni, Nicole Bodmer, Philipp K. A. Agyeman, Marc Ansari, Jochen Roessler, Nicolas X. von der Weid, Roland A. Ammann

Summary: The time to antibiotics (TTA) was not associated with poor clinical outcomes in pediatric patients with fever in neutropenia (FN) without severe disease. However, in patients with severe disease, a longer TTA was trended towards more safety relevant events (SRE).

SCIENTIFIC REPORTS (2022)

Article Pediatrics

Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics

Thomas John Jackson, Rachel Napper, Gabrielle M. Haeusler, Barry Pizer, Jessica Bate, Richard G. Grundy, Sujith Samarasinghe, Paola Angelini, Ashley Ball-Gamble, Bob Phillips, Jessica Elizabeth Morgan

Summary: This study aimed to evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN). The results showed that the use of the Australian-UK-Swiss (AUS) rule and homecare criteria allowed for safe early outpatient management of children with FN.

ARCHIVES OF DISEASE IN CHILDHOOD (2023)

Editorial Material Pediatrics

Good golly good guidance

Bob Phillips

ARCHIVES OF DISEASE IN CHILDHOOD (2023)

Review Oncology

Advances in the clinical management of high-risk Wilms tumors

Michael V. Ortiz, Christa Koenig, Amy E. Armstrong, Jesper Brok, Beatriz de Camargo, Annelies M. C. Mavinkurve-Groothuis, Thelma B. Velasquez Herrera, Rajkumar Venkatramani, Andrew D. Woods, Jeffrey S. Dome, Filippo Spreafico

Summary: Outcomes for the majority of Wilms tumor patients are excellent, but there are still subgroups with a lower survival rate. This review discusses the historical and current approach to the classification and treatment of high-risk Wilms tumors, including specific criteria for high-risk patients. Inadequate conventional therapies highlight the urgency for advancements in laboratory and early-phase clinical investigations to identify effective agents.

PEDIATRIC BLOOD & CANCER (2023)

Review Oncology

Using Evidence-Based Medicine to Support Clinical Decision-Making in RMS

Robert S. Phillips, Bas Vaarwerk, Jessica E. Morgan

Summary: Evidence-based medicine uses healthcare professional experience, research evidence, and patient preferences to inform clinical decision-making. In the field of rhabdomyosarcoma, collaborative groups like EpSSG have played a crucial role in developing evidence to support this process. This review explores key research developments in areas such as patient and public involvement, decision-making research, core outcome sets, evidence synthesis, and supporting research in rhabdomyosarcoma.

CANCERS (2023)

Review Oncology

Advances in the clinical management of high-risk Wilms tumors

Michael V. Ortiz, Christa Koenig, Amy E. Armstrong, Jesper Brok, Beatriz de Camargo, Annelies M. C. Mavinkurve-Groothuis, Thelma B. Velasquez Herrera, Rajkumar Venkatramani, Andrew D. Woods, Jeffrey S. Dome, Filippo Spreafico

Summary: Outcomes for most Wilms tumor patients are positive, but there are subgroups with a survival rate of around 50% or lower. This article discusses the historical and current approach to the classification and treatment of high-risk Wilms tumors, including those with specific histology, relapsed patients, and those in socioeconomic disadvantaged areas. As conventional therapies are insufficient, further investigation is needed to identify active agents.

PEDIATRIC BLOOD & CANCER (2023)

Article Multidisciplinary Sciences

Comparison of Bayesian methods for incorporating adult clinical trial data to improve certainty of treatment effect estimates in children

Ruth Walker, Bob Phillips, Sofia Dias

Summary: Recruiting children for randomized clinical trials poses challenges, resulting in less certainty about the safety and effectiveness of treatments compared to adults. However, it is possible to use adult evidence to better understand the effectiveness of treatments in children, and there are various statistical methods available for conducting these analyses.

PLOS ONE (2023)

Article Oncology

An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia

Constanza M. Vargas, Gabrielle A. Haeusler, Monica E. Slavin, Franz Babl, Francoise Mechinaud, Robert Phillips, Karin Thursky, Richard De Abreu Lourenco, Australian PICNICC Study Grp

Summary: The study examined the costs of in-hospital and outpatient care for febrile neutropenia (FN) in children with cancer. The results showed that FN events classified as high-risk had significantly higher costs compared to low-risk events. It was found that in-hospital admission and length of stay were the main drivers of FN costs.

PEDIATRIC BLOOD & CANCER (2023)

Article Multidisciplinary Sciences

Outcome prediction in pediatric fever in neutropenia: Development of clinical decision rules and external validation of published rules based on data from the prospective multicenter SPOG 2015 FN definition study

Marina Santschi, Roland A. Ammann, Philipp K. A. Agyeman, Marc Ansari, Nicole Bodmer, Eva Brack, Christa Koenig

Summary: This study aimed to develop new clinical decision rules (CDRs) for predicting low and high risk children with fever in neutropenia (FN), and externally validate existing CDRs. The results showed that the developed CDRs can effectively predict three different outcomes of infection severity. Additionally, six out of eleven published CDRs were found to have some reproducibility.

PLOS ONE (2023)

Article Health Care Sciences & Services

Consultant-led UK paediatric palliative care services: professional configuration, services, funding

Andre Bedendo, Sebastian Hinde, Bryony Beresford, Andrew Papworth, Bob Phillips, Chakrapani Vasudevan, Emma McLorie, Gabriella Walker, George Peat, Helen Weatherly, Richard Feltbower, Catherine Hewitt, Andrew Haynes, Fliss Murtagh, Jane Noyes, Julia Hackett, Richard Hain, Sam Oddie, Gayathri Subramanian, Lorna Fraser

Summary: The objective of this study is to gather information on the professional team members, services provided, funding sources and population served for all consultant-led specialised paediatric palliative care teams in the UK. The findings show that only six services meet the minimum criteria defined by NICE. Most services provide symptom management, specialist nursing care, end-of-life planning and care, and support for discharges and transfers. Additionally, charity funding plays a significant role in funding the services.

BMJ SUPPORTIVE & PALLIATIVE CARE (2023)

No Data Available